Tianjin JuveStar Biotechnology Co., Ltd. is invested and incubated by the fund focusing on the field of aesthetic medicine.

In September 2020, JuveStar and Raziel Therapeutics from Israel reached the exclusive clinical development and commercialization rights for RZL012 in the Greater China Region. In addition, JuveStar is actively expanding its product pipeline.